ALK7: A key type I receptor linking liver-derived signals to the regulation of adipose lipolysis

Author: Senior Product Manager of UA Views：12

This article focuses on the central role of the ALK7 receptor in the NHBE/ALK7 pathway, systematically elaborating its molecular characteristics as a type I receptor of the TGF-β receptor superfamily and the assembly mechanism of the tetrameric receptor complex, analyzing the signaling logic by which Activin E negatively regulates adipocyte lipolysis via the ALK7-SMAD2/3 axis, and exploring the differences between two small nucleic acid drug approaches—targeting ACVR1C to silence ALK7 and targeting INHBE to silence Activin E—in terms of tissue delivery and signaling coverage.

Recent Advances
Product Information

Recent Advances

ALK7: A Key Type I Receptor Connecting Liver-Derived Signals and Adipocyte Lipolysis Regulation

Summary: This article focuses on the central role of the ALK7 receptor in the NHBE/ALK7 pathway, systematically describing its molecular characteristics as a type I receptor of the TGF-β receptor superfamily and the assembly mechanism of the tetrameric receptor complex, analyzing the signaling logic by which Activin E negatively regulates adipocyte lipolysis through the ALK7-SMAD2/3 axis, and discussing the differences between two small nucleic acid drug approaches—targeting ACVR1C to silence ALK7 and targeting INHBE to silence Activin E—in terms of tissue delivery and signaling coverage.

I. Molecular Localization of ALK7 and the Assembly Mechanism of the Receptor Complex.

ALK7 is encoded by the ACVR1C gene and belongs to the type I receptor family of the TGF-β receptor superfamily. In the NHBE/ALK7 pathway, ALK7 is the core receptor on the adipocyte surface that receives liver-derived signals. Activin E signal transduction also requires the participation of type II receptors such as ActRIIA/ActRIIB, with a more pronounced dependence on ActRIIA. Upon ligand binding, 2 type I receptors and 2 type II receptors assemble into a “dimer of dimers” tetrameric receptor complex, in which the type II receptor phosphorylates and activates ALK7, thereby initiating downstream SMAD2/3 signaling. This receptor assembly mode determines that ALK7 activation is not merely a conformational change of a single receptor molecule but depends on the precise spatial pairing of type I and type II receptors, which also means that interventions targeting this pathway can be implemented at the type I receptor level or achieve mechanistic convergence at the type II receptor level.

II. Signal Flow and Lipolysis Regulation Logic of the NHBE/ALK7 Pathway.

The NHBE/ALK7 pathway connects liver-derived signals with adipose tissue lipolysis regulation and is an important research direction in current small nucleic acid drug therapy for obesity. INHBE is mainly expressed in the liver, and its encoded βE subunit forms the dimeric Activin E, which is secreted into the circulation. Activin E activates SMAD2/3 signaling through the receptor complex on the adipocyte surface, inhibits PPARγ-related transcriptional programs, reduces adipocyte lipolysis capacity, and promotes lipid storage and adipocyte hypertrophy. This signal flow clearly outlines the complete axis of “liver secretion—circulatory transport—adipose receptor—lipolysis inhibition.”

In contrast, the classical pro-lipolytic signal of adipocytes is mediated by β-adrenergic receptors, which promote lipolysis by increasing cAMP levels, activating PKA, and phosphorylating proteins such as HSL and Perilipin. The ALK7-SMAD2/3 pathway exerts a negative regulatory effect on lipolysis. Therefore, the common pharmacological goal of targeting INHBE or ALK7 is expected to attenuate this inhibitory signal and promote fat mobilization, thereby reducing fat. This “release of inhibition” rather than “direct activation” mechanism of action is the core theoretical basis for drug development targeting this pathway.

III. Differences in Tissue Delivery and Signaling Coverage Between the Two Small Nucleic Acid Drug Approaches.

Development of this pathway includes two approaches: silencing INHBE in the liver to reduce circulating Activin E levels, and silencing ACVR1C in adipocytes to reduce ALK7 expression. The two act at different steps of the same signaling axis and differ in tissue delivery, signaling coverage, and clinical validation progress.

Tissue expression determines the delivery requirements of the two approaches. INHBE has a relatively well-defined liver expression profile, allowing the use of GalNAc-conjugated siRNA for hepatocyte delivery, a relatively mature delivery technology. ALK7-targeting siRNA, however, needs to enter adipocytes, and adipose tissue delivery is technically more challenging. Tissue expression data support strong RNA enrichment of ALK7 in adipose tissue, providing target-expression-level evidence for adipocyte delivery.

In terms of signaling coverage, silencing INHBE reduces circulating ligand levels, which in theory can affect all tissues expressing the ALK7 receptor; whereas silencing ACVR1C reduces local receptor expression in adipocytes, with a scope more confined to adipose tissue itself but able to cover ALK7 receptor signaling including that of other ligands. The differential characteristics of the two approaches determine that they may form a complementary rather than substitutive relationship between breadth of efficacy and tissue specificity.

IV. Mechanistic Convergence at the Type II Receptor Level and Selectivity Considerations.

It is worth noting that drugs targeting ActRIIA/ActRIIB and blocking ligand binding share mechanistic convergence with the Activin E/ALK7 pathway at the type II receptor level; however, the effects of such molecules also involve ligands such as myostatin and Activin A, and therefore are not equivalent to specific inhibition of ALK7. This distinction has important implications for drug design: molecules acting on type II receptors affect a common node of multiple ligand pathways, with broader pharmacological effects, whereas selective targeting of ALK7 can precisely intervene in the inhibition of adipose lipolysis by Activin E while preserving other TGF-β family ligand signals. In the context of obesity treatment increasingly emphasizing precision and safety, selective inhibition of ALK7 offers a differentiated approach distinct from broad-spectrum receptor blockade.

V. Support from Human Genetics for the Regulatory Role in Fat Distribution.

In 2022, based on exome sequencing data from 362,679 participants of European ancestry in the UK Biobank, researchers analyzed the association between rare coding variants and BMI-adjusted waist-to-hip ratio; in the same year, another study integrated data from UK, Swedish, and Mexican cohorts totaling 618,375 individuals, including 160,058 participants of non-European ancestry. Both studies identified genes related to fat distribution such as INHBE and ACVR1C. Among them, loss-of-function variants in INHBE were associated with a lower BMI-adjusted waist-to-hip ratio, providing directional evidence for drug development targeting this gene. ACVR1C was independently identified as a receptor gene in the same pathway, supporting at the human genetics level the causal role of the signaling axis in which ALK7 resides in the regulation of fat distribution, and also enhancing the biological rationale for targeting this pathway in the treatment of obesity.

VI. Conclusion.

In basic research on the ALK7 receptor and drug development for metabolic diseases, high-quality recombinant ALK7 protein is a core tool for dissecting its binding mechanism with the Activin E ligand, evaluating receptor complex assembly, and screening targeted intervention molecules. The GST tag facilitates efficient purification via glutathione affinity chromatography and can serve as a detection tag for analyses such as enzyme-linked immunosorbent assay and surface plasmon resonance. In response to the needs of ALK7 functional research and obesity therapeutic drug development, Univ provides ACVR1C(ALK7) GST Tag Protein, Human. This product is suitable for applications such as binding activity analysis of ALK7 with Activin E and type II receptors, research on ALK7-mediated SMAD2/3 signaling pathway activation, in vitro evaluation of small nucleic acid drugs and receptor blockers targeting ACVR1C, and mechanistic exploration of the NHBE/ALK7 pathway.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next